| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,473 |
3,893 |
$668K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,001 |
3,348 |
$649K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
579 |
503 |
$490K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
199 |
144 |
$360K |
| 71045 |
Radiologic examination, chest; single view |
412 |
357 |
$66K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
798 |
627 |
$59K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
748 |
645 |
$48K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,602 |
7,057 |
$46K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
249 |
214 |
$46K |
| 80053 |
Comprehensive metabolic panel |
6,541 |
5,079 |
$44K |
| 36415 |
Collection of venous blood by venipuncture |
10,754 |
7,827 |
$33K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
356 |
305 |
$29K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
238 |
218 |
$23K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,544 |
1,748 |
$19K |
| 73630 |
|
486 |
369 |
$17K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
216 |
183 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
392 |
343 |
$15K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
227 |
189 |
$11K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
13 |
12 |
$10K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
134 |
122 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
42 |
39 |
$7K |
| 80050 |
General health panel |
40 |
39 |
$7K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
311 |
272 |
$6K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
17 |
14 |
$6K |
| 80061 |
Lipid panel |
597 |
532 |
$6K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
550 |
486 |
$5K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
34 |
27 |
$5K |
| 82607 |
|
350 |
308 |
$3K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
14 |
12 |
$3K |
| 83540 |
|
698 |
610 |
$3K |
| 70450 |
Computed tomography, head or brain; without contrast material |
14 |
12 |
$3K |
| 86769 |
|
85 |
65 |
$2K |
| 83550 |
|
407 |
360 |
$2K |
| 84484 |
|
202 |
140 |
$2K |
| 82728 |
|
230 |
198 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
74 |
59 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
74 |
59 |
$2K |
| 81025 |
|
257 |
222 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
59 |
56 |
$1K |
| 83690 |
|
324 |
267 |
$1K |
| 86003 |
|
13 |
12 |
$1K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
12 |
12 |
$1K |
| 81001 |
|
408 |
356 |
$1K |
| 83655 |
|
83 |
81 |
$1K |
| 85027 |
|
102 |
98 |
$645.65 |
| 85610 |
|
207 |
166 |
$639.69 |
| 97161 |
|
13 |
13 |
$505.36 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
14 |
14 |
$409.25 |
| 83735 |
|
103 |
87 |
$405.58 |
| 87510 |
|
31 |
29 |
$404.87 |
| 87480 |
|
31 |
29 |
$404.87 |
| 87660 |
|
31 |
29 |
$404.87 |
| 82105 |
|
39 |
30 |
$389.01 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
15 |
12 |
$361.42 |
| 87081 |
|
54 |
40 |
$300.98 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
27 |
12 |
$284.94 |
| 86706 |
|
37 |
24 |
$254.54 |
| 97116 |
|
17 |
13 |
$228.05 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
28 |
25 |
$207.61 |
| 82746 |
|
29 |
24 |
$196.52 |
| 86780 |
|
14 |
12 |
$185.36 |
| 86708 |
|
20 |
13 |
$140.26 |
| 86850 |
|
14 |
12 |
$32.73 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12 |
12 |
$9.66 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
99 |
44 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
131 |
91 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
144 |
128 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
106 |
58 |
$0.00 |